Orphazyme: Jumps ahead of FDA decision

Strategic Partners A/S

17/06/2021 08:50

** Shares in Orphazyme  ORPHA.CO  rise 21% on Thursday as
the Danish drug developer awaits the U.S. FDA's decision on its
genetic disorder drug 
    ** FDA is set to decide on whether to approve the company's
lead candidate, arimoclomol, to treat Niemann-Pick Disease Type
C (NPC) 
    ** Nordnet, however, says that even if Orphazyme gets clear
approval, it will not explain and defend the development
    ** It adds that the company has for the previous two times
not been able to prove projects' value in final studies
    ** Orphazyme has recently become one of so-called
meme-stocks that have a high-short interest  urn:newsml:reuters.com:*:nL5N2NW4IH
    ** Stock is the top performer on Copenhagen all-share index
 .OMXCPI 
    ** It's U.S.-listed shares  ORPH.O  closed about 65% higher
on Wednesday  urn:newsml:reuters.com:*:nL3N2NY3OL 

 ((paulina.cwikowska@tr.com))